BioCorRx Statistics
Total Valuation
BioCorRx has a market cap or net worth of 7.41 million. The enterprise value is 10.64 million.
| Market Cap | 7.41M |
| Enterprise Value | 10.64M |
Important Dates
The next estimated earnings date is Tuesday, March 31, 2026.
| Earnings Date | Mar 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioCorRx has 24.29 million shares outstanding. The number of shares has increased by 67.95% in one year.
| Current Share Class | 24.29M |
| Shares Outstanding | 24.29M |
| Shares Change (YoY) | +67.95% |
| Shares Change (QoQ) | +6.77% |
| Owned by Insiders (%) | 33.29% |
| Owned by Institutions (%) | n/a |
| Float | 13.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.82 |
| PB Ratio | -0.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.06 |
| EV / Sales | 11.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.10
| Current Ratio | 0.10 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.40 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -82.89% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 72.25% |
| Revenue Per Employee | 316,121 |
| Profits Per Employee | -1.72M |
| Employee Count | 3 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.02% in the last 52 weeks. The beta is 0.17, so BioCorRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -29.02% |
| 50-Day Moving Average | 0.38 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 46.50 |
| Average Volume (20 Days) | 1,387 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, BioCorRx had revenue of 948,362 and -5.16 million in losses. Loss per share was -0.33.
| Revenue | 948,362 |
| Gross Profit | 589,549 |
| Operating Income | -5.42M |
| Pretax Income | -4.27M |
| Net Income | -5.16M |
| EBITDA | -5.24M |
| EBIT | -5.42M |
| Loss Per Share | -0.33 |
Balance Sheet
The company has 287,688 in cash and 2.78 million in debt, giving a net cash position of -2.49 million or -0.10 per share.
| Cash & Cash Equivalents | 287,688 |
| Total Debt | 2.78M |
| Net Cash | -2.49M |
| Net Cash Per Share | -0.10 |
| Equity (Book Value) | -12.76M |
| Book Value Per Share | -0.67 |
| Working Capital | -13.58M |
Cash Flow
| Operating Cash Flow | -1.70M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 62.16% |
| Operating Margin | -571.74% |
| Pretax Margin | -449.74% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioCorRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -67.95% |
| Shareholder Yield | -67.95% |
| Earnings Yield | -69.58% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 22, 2019. It was a reverse split with a ratio of 0.01.
| Last Split Date | Jan 22, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
BioCorRx has an Altman Z-Score of -20.45 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.45 |
| Piotroski F-Score | 5 |